Company / Cash & Equivalents
Larimar Therapeutics, Inc. Cash & Equivalents History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$27.2M
FY2019
5-year range
$27.2M / $58.1M
FY2015-FY2019
Trend
-44.8%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 6 years, ranging from $10M in FY2014 to $58M in FY2016.
Based on SEC 10-K filings.
$27M in FY2019 with a 5-year CAGR of +22.3%.
Declined from $36M to $27M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -22.3%
- 5-Year CAGR
- +22.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +22.3%, indicating consistent growth.
- In FY2019, cash & equivalents decreased 44.8% year-over-year.
- Peak cash & equivalents was recorded in FY2016.
- Lowest cash & equivalents in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $27.2M | -44.8% |
| FY2018 | $49.3M | +38.6% |
| FY2017 | $35.6M | -38.7% |
| FY2016 | $58.1M | +63.6% |
| FY2015 | $35.5M | +257.5% |
| FY2014 | $9.9M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026